Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - IMMUNIC, INC. | d755985dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
July 9, 2014
VITAL THERAPIES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36201 | 56-2358443 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
15010 Avenue of Science, Suite 200
San Diego, CA 92128
(Address of principal executive offices, including zip code)
(858) 673-6840
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Information. |
On July 9, 2014, Vital Therapies, Inc. issued a press release providing an update on the status of its clinical trials of ELAD®, a cell-based therapy targeting treatment of acute liver failure, and on advice received from the European Medical Agency through the Scientific Advice Working Party process. As a part of this update, Vital Therapies, Inc. reported enrollment of 123 subjects in its VTI-208 Phase 3 randomized, controlled clinical trial targeting 200 subjects with alcohol-induced liver decompensation, or AILD. A copy of this press release is attached hereto as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit No. |
Description | |
| 99.1 | Press Release dated July 9, 2014, of the registrant. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VITAL THERAPIES, INC. | ||
| By: | /s/ Michael V. Swanson | |
| Michael V. Swanson Chief Financial Officer | ||
Date: July 9, 2014
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press Release dated July 9, 2014, of the registrant. | |